Publications

Yana Najjar

Augustin RC, Delgoffe GM, Najjar YG. Characteristics of the Tumor Microenvironment That Influence Immune Cell Functions: Hypoxia, Oxidative Stress, Metabolic Alterations. Cancers (Basel). 2020 Dec 17;12(12): doi: 10.3390/cancers12123802. PubMed PMID: 33348579; PMCID: PMC7765870.
Zhang SH, Liu R, Siripong N, Kirkwood JM, Holtzman MP, Davar D, Najjar Y, Marshall K, Jackson Cullison SR, Houston NA, Switzer G, Ferris LK. Thick melanoma is associated with low melanoma knowledge and low perceived health competence, but not delays in care. J Am Acad Dermatol. 2020 Aug;83(2):587-590. doi: 10.1016/j.jaad.2019.05.068. PubMed PMID: 31150702.
Najjar YG, Puligandla M, Lee SJ, Kirkwood JM. An updated analysis of 4 randomized ECOG trials of high-dose interferon in the adjuvant treatment of melanoma. Cancer. 2019 Sep 1;125(17):3013-3024. doi: 10.1002/cncr.32162. PubMed PMID: 31067358; PMCID: PMC7428054.
Najjar YG, Menk AV, Sander C, Rao U, Karunamurthy A, Bhatia R, Zhai S, Kirkwood JM, Delgoffe GM. Tumor cell oxidative metabolism as a barrier to PD-1 blockade immunotherapy in melanoma. JCI Insight. 2019 Mar 7;4(5): doi: 10.1172/jci.insight.124989. PubMed PMID: 30721155; PMCID: PMC6483505.
Eroglu Z, Holmen SL, Chen Q, Khushalani NI, Amaravadi R, Thomas R, Ahmed KA, Tawbi H, Chandra S, Markowitz J, Smalley I, Liu JKC, Chen YA, Najjar YG, Karreth FA, Abate-Daga D, Glitza IC, Sosman JA, Sondak VK, Bosenberg M, Herlyn M, Atkins MB, Kluger H, Margolin K, Forsyth PA, Davies MA, Smalley KSM. Melanoma central nervous system metastases: An update to approaches, challenges, and opportunities. Pigment Cell Melanoma Res. 2019 May;32(3):458-469. doi: 10.1111/pcmr.12771. PubMed PMID: 30712316; PMCID: PMC7771318.
Butterfield LH, Disis ML, Fox BA, Kaufman DR, Khleif SN, Wang E, Society for Immunotherapy of Cancer Immuno-Oncology Biomarkers: State of the Art workshop speakers.. SITC 2018 workshop report: Immuno-Oncology Biomarkers: State of the Art. J Immunother Cancer. 2018 Dec 4;6(1):138. doi: 10.1186/s40425-018-0453-4. PubMed PMID: 30514399; PMCID: PMC6278162.
Roy S, Pradhan D, Ernst WL, Mercurio S, Najjar Y, Parikh R, Parwani AV, Pai RK, Dhir R, Nikiforova MN. Next-generation sequencing-based molecular characterization of primary urinary bladder adenocarcinoma. Mod Pathol. 2017 Aug;30(8):1133-1143. doi: 10.1038/modpathol.2017.33. PubMed PMID: 28548125.
Najjar YG, Ding F, Lin Y, VanderWeele R, Butterfield LH, Tarhini AA. Melanoma antigen-specific effector T cell cytokine secretion patterns in patients treated with ipilimumab. J Transl Med. 2017 Feb 21;15(1):39. doi: 10.1186/s12967-017-1140-9. PubMed PMID: 28222797; PMCID: PMC5319167.
Najjar YG, Rayman P, Jia X, Pavicic PG Jr, Rini BI, Tannenbaum C, Ko J, Haywood S, Cohen P, Hamilton T, Diaz-Montero CM, Finke J. Myeloid-Derived Suppressor Cell Subset Accumulation in Renal Cell Carcinoma Parenchyma Is Associated with Intratumoral Expression of IL1β, IL8, CXCL5, and Mip-1α. Clin Cancer Res. 2017 May 1;23(9):2346-2355. doi: 10.1158/1078-0432.CCR-15-1823. PubMed PMID: 27799249; PMCID: PMC5411325.
Najjar YG, Kirkwood JM. Neoadjuvant treatment for melanoma: current challenges and future perspectives. Melanoma Manag. 2016 Jun;3(2):149-159. doi: 10.2217/mmt-2015-0001. PubMed PMID: 30190883; PMCID: PMC6094612.

<< Investigators Search

Top